Act 3: The Stacking Question What Longevity Experts Say About Combining Both The most sophisticated practitioners in the longevity space don't typically ask, "Should I use GLP-1 or BPC-157?" Instead, they ask, "When does each one belong in a protocol, and can they safely coexist?" The Complementary Logic Longevity-focused physicians and sports medicine practitioners have begun articulating a clear rationale for combining these compounds in specific patient profiles: The GLP-1 Layer: Addresses the metabolic side (reducing fat, improving insulin, lowering cardiovascular risk)
Our GLP-1 agonist therapies, Semaglutide and Tirzepatide for weight loss, offer a proven path to lasting weight loss
Chrousos G
Most semaglutide users find that appetite is strongest in the morning and diminishes throughout the day
A SURPASS-4 clinical trial involved patients with cardiovascular diseases such as peripheral arterial disease, coronary artery disease, stroke, and myocardial infarction
A provider-guided assessment should precede any GLP-1 therapy, including cardiovascular history, thyroid status, and gastrointestinal tolerance